Fritsma Factor recently posted a brief survey asking laboratory scientists to characterize the sensitivity of their “routine” activated partial thromboplastin time (APTT) assay for lupus anticoagulant (LAC). This is a three-question follow-up survey for physicians. To go direct to the survey, select APTT Sensitivity Survey. For further explanation, please continue reading.
The activated partial thromboplastin time (APTT) assay is used to monitor anticoagulant therapy, screen for coagulation factor deficiencies as a means to predict risk of bleeding, and to screen for lupus anticoagulant (LAC, lupus-like anticoagulant, lupus antibody), which may be associated with thrombosis and or recurrent miscarriage. A number of APTT reagents are available; these employ a variety of activators and phospholipid compositions, rendering them highly, moderately, or minimally sensitive to lupus anticoagulants. We propose to learn which of these three applications of the APTT are of most importance to clinicians, and to determine clinician understanding of APTT reagent LAC sensitivity. Investigators are Ellinor Peerschke, PhD, Elizabeth Van Cott, MD, Dorothy (Dot) Adcock-Funk, MD, and Marisa B. Marques, MD. Ankush Randhawa and George Fritsma assisted with survey development. Thanks!